These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparative cardiovascular effects of different progestins in menopause. Rosano GM; Fini M Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197 [TBL] [Abstract][Full Text] [Related]
3. Is hormone replacement therapy cardioprotective? Decision-making after the heart and estrogen/progestin replacement study. McPherson R Can J Cardiol; 2000 Jan; 16 Suppl A():14A-9A. PubMed ID: 10653926 [TBL] [Abstract][Full Text] [Related]
5. [Present position of the hormonal replacement therapy]. Fait T; Vokrouhlická J; Vrablík M; Jenícek J Cas Lek Cesk; 2004; 143(7):447-52. PubMed ID: 15373286 [TBL] [Abstract][Full Text] [Related]
6. Postmenopausal hormone therapy and the risk of cardiovascular disease. Stramba-Badiale M J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340 [TBL] [Abstract][Full Text] [Related]
7. Postmenopausal hormone replacement therapy and the prevention of cardiovascular disease: a review. Abramson BL J Cardiovasc Risk; 2002 Dec; 9(6):309-14. PubMed ID: 12478199 [TBL] [Abstract][Full Text] [Related]
8. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657 [TBL] [Abstract][Full Text] [Related]
9. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Rosano GM; Vitale C; Fini M Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159 [TBL] [Abstract][Full Text] [Related]
10. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes. Corrao G; Zambon A; Nicotra F; Fornari C; La Vecchia C; Mezzanzanica M; Nappi RE; Merlino L; Cesana G Maturitas; 2007 Jul; 57(3):315-24. PubMed ID: 17485182 [TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease. Windler E; Zyriax BC; Eidenmüller B; Boeing H Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571 [TBL] [Abstract][Full Text] [Related]
16. Postmenopausal hormone replacement therapy and major clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia. Dick SE; DeWitt DE; Anawalt BD Am J Manag Care; 2002 Jan; 8(1):95-104; quiz 105-6. PubMed ID: 11814176 [TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119 [TBL] [Abstract][Full Text] [Related]
19. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. Kuhl H; Stevenson J Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155 [TBL] [Abstract][Full Text] [Related]
20. HRT and the primary prevention of cardiovascular disease. Stevenson JC Maturitas; 2007 May; 57(1):31-4. PubMed ID: 17383835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]